Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BRNS NASDAQ:HALO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBRNSBarinthus Biotherapeutics$1.19+3.9%$1.21$0.64▼$2.92$45.99M-0.7358,013 shs26,007 shsHALOHalozyme Therapeutics$71.61+0.7%$58.36$42.01▼$72.33$8.32B1.172.03 million shs1.86 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBRNSBarinthus Biotherapeutics-0.78%-7.32%-42.13%+40.74%-10.24%HALOHalozyme Therapeutics+1.64%+9.21%+27.20%+32.33%+16.74%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBRNSBarinthus Biotherapeutics2.86 of 5 stars3.53.00.00.02.40.81.3HALOHalozyme Therapeutics4.6585 of 5 stars2.11.00.04.44.02.54.4Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBRNSBarinthus Biotherapeutics 3.00Buy$3.00153.16% UpsideHALOHalozyme Therapeutics 2.18Hold$67.11-6.28% DownsideCurrent Analyst Ratings BreakdownLatest HALO, BRNS, GWP, and SER Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/18/2025HALOHalozyme TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$75.00 ➝ $80.008/7/2025HALOHalozyme TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$60.00 ➝ $63.008/6/2025HALOHalozyme TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetMarket Outperform ➝ Market Outperform$78.00 ➝ $91.008/6/2025HALOHalozyme TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$72.00 ➝ $75.008/6/2025HALOHalozyme TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeEqual Weight ➝ Overweight$62.00 ➝ $75.007/16/2025HALOHalozyme TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$58.00 ➝ $60.007/10/2025HALOHalozyme TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$55.005/29/2025HALOHalozyme TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$72.00(Data available from 8/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBRNSBarinthus Biotherapeutics$14.97M3.19N/AN/A$2.54 per share0.47HALOHalozyme Therapeutics$1.02B8.25$4.76 per share15.04$2.84 per share25.21Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBRNSBarinthus Biotherapeutics-$61.07M-$1.73N/AN/AN/AN/A-54.70%-44.75%11/5/2025 (Estimated)HALOHalozyme Therapeutics$444.09M$4.3716.3911.510.3847.28%150.85%29.19%10/30/2025 (Estimated)Latest HALO, BRNS, GWP, and SER EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025BRNSBarinthus Biotherapeutics-$0.29-$0.52-$0.23-$0.52N/AN/A8/5/2025Q2 2025HALOHalozyme Therapeutics$1.23$1.54+$0.31$1.33$282.66 million$325.72 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBRNSBarinthus BiotherapeuticsN/AN/AN/AN/AN/AHALOHalozyme TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBRNSBarinthus BiotherapeuticsN/A7.897.89HALOHalozyme Therapeutics4.548.367.01Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBRNSBarinthus Biotherapeutics25.20%HALOHalozyme Therapeutics97.79%Insider OwnershipCompanyInsider OwnershipBRNSBarinthus Biotherapeutics10.70%HALOHalozyme Therapeutics2.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBRNSBarinthus Biotherapeutics10740.34 million36.02 millionN/AHALOHalozyme Therapeutics390116.97 million114.16 millionOptionableHALO, BRNS, GWP, and SER HeadlinesRecent News About These CompaniesHalozyme Therapeutics (NASDAQ:HALO) Sets New 12-Month High After Analyst UpgradeAugust 21 at 10:44 AM | marketbeat.comBI Asset Management Fondsmaeglerselskab A S Has $23.83 Million Stake in Halozyme Therapeutics, Inc. $HALOAugust 21 at 6:15 AM | marketbeat.comFuller & Thaler Asset Management Inc. Acquires 242,167 Shares of Halozyme Therapeutics, Inc. $HALOAugust 21 at 5:37 AM | marketbeat.comHalozyme Therapeutics (NASDAQ:HALO) Reaches New 52-Week High on Analyst UpgradeAugust 21 at 2:26 AM | americanbankingnews.comHalozyme Therapeutics (NASDAQ:HALO) Stock Price Expected to Rise, Morgan Stanley Analyst SaysAugust 20 at 9:24 AM | marketbeat.comBrandywine Global Investment Management LLC Makes New $4.76 Million Investment in Halozyme Therapeutics, Inc. $HALOAugust 20 at 5:28 AM | marketbeat.comWhat 7 Analyst Ratings Have To Say About Halozyme TherapeuticsAugust 19 at 12:18 AM | benzinga.comCresset Asset Management LLC Has $19.55 Million Stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO)August 19 at 6:15 AM | marketbeat.comHalozyme Therapeutics (NASDAQ:HALO) Price Target Raised to $80.00 at Morgan StanleyAugust 19 at 3:13 AM | americanbankingnews.comTravere Therapeutics Reaches 80-Plus Relative Strength Rating BenchmarkAugust 18 at 12:13 PM | msn.comKymera Therapeutics Shows Market Leadership With Jump To 84 RS RatingAugust 18 at 12:13 PM | msn.comHalozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Bought by Boston PartnersAugust 17, 2025 | marketbeat.comMineralys Therapeutics Scores Relative Strength Rating Upgrade; Hits Key BenchmarkAugust 15, 2025 | msn.comInsider Selling: Halozyme Therapeutics, Inc. (NASDAQ:HALO) CEO Sells 20,000 Shares of StockAugust 15, 2025 | marketbeat.comHalozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by E Fund Management Co. Ltd.August 15, 2025 | marketbeat.comHalozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Bought by Prudential PLCAugust 15, 2025 | marketbeat.comVirtu Financial LLC Has $880,000 Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)August 14, 2025 | marketbeat.comEntropy Technologies LP Buys Shares of 11,452 Halozyme Therapeutics, Inc. (NASDAQ:HALO)August 14, 2025 | marketbeat.comHalozyme Therapeutics, Inc. (NASDAQ:HALO) Position Cut by Vanguard Group Inc.August 14, 2025 | marketbeat.com66,240 Shares in Halozyme Therapeutics, Inc. (NASDAQ:HALO) Acquired by King Luther Capital Management CorpAugust 13, 2025 | marketbeat.comHalozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by Charles Schwab Investment Management Inc.August 13, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeHALO, BRNS, GWP, and SER Company DescriptionsBarinthus Biotherapeutics NASDAQ:BRNS$1.18 +0.05 (+3.95%) Closing price 03:59 PM EasternExtended Trading$1.20 +0.01 (+1.27%) As of 05:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer. It is also involved in the development of partnered candidates, such as AB-729-202, which is under phase 2a studies for the treatment of patients with chronic HBV infection; VTP-600, an immunotherapy candidate under phase 1 studies as a potential treatment for NSCLC in combination with standard of care treatment, chemotherapy, and pembrolizumab; VTP-500, a prophylactic vaccine product candidate under phase 1 studies to prevent infection and subsequent disease caused by the MERS coronavirus; and VTP-400, a prophylactic vaccine candidate under phase 1 studies to prevent shingles in adults aged 50 years and older. In addition, the company offers Vaxzevria (formerly VTP-900 and AZD1222), a prophylactic vaccine for the prevention of COVID-19 Infection. Further, it has license, research and development, and collaboration agreements with OUI, NIH, IMC, CanSino, CRUK; VOLT; and Arbutus. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Didcot, the United Kingdom.Halozyme Therapeutics NASDAQ:HALO$71.61 +0.48 (+0.67%) Closing price 04:00 PM EasternExtended Trading$71.20 -0.41 (-0.57%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Robotics Stocks at the Heart of the Robotics Revolution Analog Devices and an AI-Driven Semiconductor Supercycle Palantir is Selling Off, BigBear.ai Could Be Your Hedge ASML Has Entered Buy Territory, But Only For Patient Investors Lowe’s Builds Value for Investors: Still a Good Buy in 2025 Target: Missing the Mark in 2025—Downtrend May Continue Toll Brothers: A Great Buy and Hold Stock With Risks in 2025 Amazon Stock Sets Up for Breakout After Bullish Crossover Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access